|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
28.880 -0.200 (-0.688%) Ranking Overview
Ranking based on 2 research report(s)
Average Ranking 3.00
|
Strong Buy (1)
0
|
Buy (2)
1
|
Hold (3)
0
|
Sell (4)
1
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2025 | EPS | 227.00 RMB (cts) | |
| Net Profit | 2,023.25 RMB (MIL) | DPS | 143.00 RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2026 | 2,078.65 | 231.00 | 155.00 | -- | 2,084.30 | 2,073.00 |
| 2027 | 2,258.45 | 251.00 | 168.50 | -- | 2,274.00 | 2,242.90 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2026 | 2,073.00 | 233.00 | 145.00 | CICC | Outperform | 39.00 | 13/04/2026 | |
| 2026 | 2,084.30 | 229.00 | 165.00 | GOLDMAN SACHS | Sell | 22.99 | 05/02/2026 | |
| 2027 | 2,274.00 | 256.00 | 159.00 | CICC | -- | -- | 13/04/2026 | |
| 2027 | 2,242.90 | 246.00 | 178.00 | GOLDMAN SACHS | -- | -- | 05/02/2026 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 21/04/2026 18:00 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,023,249 |
| %Change | -1.836% |
| EPS / (LPS) | RMB 2.270 |
| NBV Per Share (¥) | RMB 15.642 |